P62: dupilumab demonstrates rapid and sustained improvements in daily asthma ‐related symptoms in patients with uncontrolled, moderate‐to‐severe asthma: data from the liberty asthma quest study

Internal Medicine Journal,Volume 48, Issue S6, Page 22-23, November 2018.
Source: Internal Medicine Journal - Category: Internal Medicine Source Type: research